GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered? - McDermott Will & Emery

GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?

Overview


Chris Bruno will speak on a panel for LSPN Connect on the topic of “GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?” Discussion will include an overview of the role of skinny labelling in the US FDA’s regulation of drug products and the implications of the recent GSK v Teva ruling on patent strategies for brand and generic drug manufacturers.

Click here for more information and to register.

Dig Deeper

Webinar / McDermott IP Focus / April 6 and April 21, 2023

McDermott IP Focus (Japan) 2023

Webinar Series / / October 5, November 9, December 8

McDermott IP Focus

Chicago, Illinois / Speaking Engagements / October 1, 2022

A Debate on Covid Patents and Global Patent Protection

Stanford, California / Speaking Engagements / September 14, 2022

Patent, Licensing and Managing Conflict of Interest

Chicago, Illinois / Speaking Engagements / May 12, 2022

How to Pitch and Win Business—What Really Works and What Doesn’t

Get In Touch